Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

The eye as a window to the brain

Project description

A technology for the ‘brain’s window’

Brain diseases are one of the current major challenges in healthcare. With the increase in life expectancy and ageing population, they are the leading cause of disability and the second leading cause of death worldwide. The greatest unmet needs, however, are improved and more cost-effective diagnostic and monitoring tools. The EU-funded NeuroRetina project is developing software solutions to efficiently process retina image data for neurological applications. The team uses the retina as ‘a window to the brain’ and an already established hardware imaging tool to capture retinal images in less than 5 minutes. The data is then analysed with Nocturne’s technology, and a report is generated for the physician, removing the technical barriers and providing unique insights.

Objective

Nocturne GmbH, founded in 2018, is a spin-off from the Charité – Universitätsmedizin Berlin, Germany developing software solutions to efficiently process retina image data for neurological applications at scale across devices using advanced AI-based analysis. The innovative and unique technology developed tackles one the current major challenges in healthcare, the rapidly increasing burden of brain diseases. With the increase of life expectancy and aging population neurological disorders are the leading cause of disability and the second leading cause of death worldwide. The greatest unmet needs are better, faster and more cost-effective diagnostic and monitoring tools that could be widely available and have the potential to detect these diseases at the earliest stage in order to delay disability and provide each patient with a personalized treatment.
To address this the team of Nocturne identified two major opportunities, the use of the retina as a window to the brain, and an already established on the market hardware imaging technology, cost-effective, widely available with no burden for the patient that can capture retinal images in less than 5 minutes.
With its product, Nocturne addresses customers in pharmaceutical research, academia, and clinical care. In Germany alone, more than 1 million patients suffer from relevant diseases like Multiple Sclerosis, Parkinson’s disease, and others. We estimate the annual market volume in Germany alone at 350 million€, in Europe at 2 billion€.
At market entry, Nocturne product is a CE-certified local installable web service, which accepts data from standard retinal imaging devices.
The data are then analyzed with Nocturne’s technology, and a report is generated for the physician. The pricing is based on a pay-per-analysis, a model commonly used, for example, in radiology.
Our focus is by removing the technical barriers and by providing unique insights into the diseases to enable better disease management and patient care.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-CSA - HORIZON Coordination and Support Actions

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIE-2021-SCALEUP-01

See all projects funded under this call

Coordinator

NOCTURNE GMBH
Net EU contribution
€ 75 000,00
Address
SCHONHAUSER ALLEE 177
10119 Berlin
Germany
SME
Yes
Region
Berlin Berlin Berlin
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
No data